Evidence map›Paper›PMID 36671410›Full record

ReviewBiomolecules2022

Message in a Scaffold: Natural Biomaterials for Three-Dimensional (3D) Bioprinting of Human Brain Organoids.

Pierre Layrolle, Pierre Payoux, Stéphane Chavanas

Abstract readReview
In one paragraph

Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Biomaterials in organoid research: current state and future directions.Frontiers in bioengineering and biotechnology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pierre LayrolleINSERM, Université Paul Sabatier, Toulouse NeuroImaging Center (ToNIC), UMR 1214, CHU Purpan, 31024 Toulouse, France.ORCID 0000-0001-9800-5210
Pierre PayouxINSERM, Université Paul Sabatier, Toulouse NeuroImaging Center (ToNIC), UMR 1214, CHU Purpan, 31024 Toulouse, France.
Stéphane ChavanasINSERM, Université Paul Sabatier, Toulouse NeuroImaging Center (ToNIC), UMR 1214, CHU Purpan, 31024 Toulouse, France.ORCID 0000-0003-4323-2656

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain organoids are invaluable tools for pathophysiological studies or drug screening, but there are still challenges to overcome in making them more reproducible and relevant. Recent advances in three-dimensional (3D) bioprinting of human neural organoids is an emerging approach that may overcome the limitations of self-organized organoids. It requires the development of optimal hydrogels, and a wealth of research has improved our knowledge about biomaterials both in terms of their intrinsic properties and their relevance on 3D culture of brain cells and tissue. Although biomaterials are rarely biologically neutral, few articles have reviewed their roles on neural cells. We here review the current knowledge on unmodified biomaterials amenable to support 3D bioprinting of neural organoids with a particular interest in their impact on cell homeostasis. Alginate is a particularly suitable bioink base for cell encapsulation. Gelatine is a valuable helper agent for 3D bioprinting due to its viscosity. Collagen, fibrin, hyaluronic acid and laminin provide biological support to adhesion, motility, differentiation or synaptogenesis and optimize the 3D culture of neural cells. Optimization of specialized hydrogels to direct differentiation of stem cells together with an increased resolution in phenotype analysis will further extend the spectrum of possible bioprinted brain disease models.

Indexed as

Biocompatible MaterialsBioprintingBrainHumansHydrogelsOrganoidsTissue EngineeringBiocompatible MaterialsHydrogels3D bioprintingbiomaterialsbrain organoiddisease modelinduced pluripotent stem cellsneural stem cellneuronscaffold

Identifiers

PMID36671410
PMCPMC9855696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.